Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
237 hedge funds and large institutions have $4.11B invested in Momenta Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 97 increasing their positions, 58 reducing their positions, and 17 closing their positions.
241% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 17
174% more call options, than puts
Call options by funds: $5.26M | Put options by funds: $1.92M
67% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 58
30% more capital invested
Capital invested by funds: $3.17B → $4.11B (+$941M)
20% more funds holding
Funds holding: 198 → 237 (+39)
5.57% more ownership
Funds ownership: 99.21% → 104.78% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$46.9M |
| 2 |
BlackRock
New York
|
+$42.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$32.2M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$30.1M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$23.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$49.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$26.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$22.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.6M |
MNTA Hedge Fund Activity: Q2 2020 in Review
237 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2020, worth a combined $4.11B — up 30% from $3.17B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new MNTA positions and 17 closed out — a net gain of 41 holders — while 97 added to existing stakes and 58 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $46.9M. The largest seller was Camber Capital Management, cutting an estimated $49.4M.
- 237 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2020, up from 198 in Q1 2020.
- Funds reported $4.11B of Momenta Pharmaceuticals, Inc. stock for Q2 2020, up 30% quarter-over-quarter.
- 58 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2020 and 17 closed out, a net change of +41 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2020 was Janus Henderson Group, an estimated $46.9M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q2 2020 was Camber Capital Management, an estimated $49.4M sold.
Based on aggregated 13F filings for Q2 2020.